Prescription ·Strong evidence ·Reviewed May 2026
Glipizide is a second-generation sulfonylurea used to improve glycemic control in adults with type 2 diabetes. It stimulates insulin release from functioning pancreatic beta cells and is typically used when diet, exercise, and metformin alone are insufficient to control blood glucose.
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 1.0–2.0%, rapid onset of glucose lowering, effective in early-stage type 2 diabetes with residual beta cell function. 10 sources indexed (1994–2025), with 9 interaction records on file.
Core mechanism
Binds to the sulfonylurea receptor 1 (SUR1) on pancreatic beta cell ATP-sensitive potassium channels, causing channel closure and membrane depolarization. This triggers calcium influx through voltage-gated calcium channels, resulting in insulin granule exocytosis. The effect is glucose-independent, meaning insulin is released regardless of ambient glucose levels.
Immediate-release should be taken 30 minutes before meals for optimal postprandial glucose control. Extended-release taken with breakfast.
Both glipizide and berberine lower blood glucose. Glipizide stimulates insulin secretion; berberine activates AMPK. Combined use significantly increases hypoglycemia risk.
Recommendation: Monitor blood glucose closely. If adding berberine, start at low dose and may need glipizide dose reduction. Inform your prescriber.
Berberine HCl lowers blood glucose independently of sulfonylurea therapy. Glipizide can cause hypoglycemia by increasing insulin release, so adding Berberine HCl can push glucose too low. Risk is higher with missed meals, low-carbohydrate dieting, older age, kidney disease, or recent weight loss.
Recommendation: Do not add Berberine HCl to glipizide without a glucose-monitoring plan. Check glucose more often for the first 1-2 weeks and ask your prescriber whether glipizide dose reduction is appropriate if readings fall.
Vanadium has insulin-like and insulin-sensitizing activity in PubMed-indexed human diabetes studies. Glipizide stimulates insulin release and can cause hypoglycemia, so adding vanadium may increase the chance of low blood sugar, particularly in older adults, kidney disease, missed meals, or dose escalation.
Recommendation: Avoid starting vanadium while taking glipizide unless your diabetes clinician approves and monitoring is planned. Check glucose more often during any vanadium change and report recurrent lows, sweating, tremor, confusion, or nighttime symptoms. Do not self-adjust glipizide dose without clinician guidance.
Chromium supplementation can lower fasting glucose and HbA1c in type 2 diabetes by improving insulin signaling. Stacked on top of a sulfonylurea like glipizide, which itself drives endogenous insulin release, this additive glucose-lowering can produce hypoglycemia, especially during the first weeks after starting chromium or after dose changes. Older adults and patients with renal impairment are most vulnerable.
Recommendation: If you take glipizide, do not start chromium without telling your prescriber. Check fingerstick glucose more often (especially before meals and at bedtime) for the first 2-4 weeks, and ask whether the glipizide dose should be reduced.
Alpha-lipoic acid (ALA) improves insulin sensitivity and lowers fasting glucose and HbA1c in meta-analyses of diabetic patients. ALA has also triggered insulin autoimmune syndrome (Hirata syndrome), producing severe spontaneous hypoglycemia. Layered on glipizide, which itself forces insulin secretion, the additive glucose-lowering can produce hypoglycemia, especially in older adults or after missed meals.
Recommendation: If you take glipizide, do not start ALA without telling your prescriber. Monitor fingerstick glucose more often during the first 4 weeks and after any dose change. Seek urgent care if you have repeated unexplained hypoglycemia, which can signal insulin autoimmune syndrome.
Fenugreek extracts lower fasting glucose and HbA1c in type 2 diabetes meta-analyses. Stacked on glipizide, which already forces pancreatic insulin secretion, the additive glucose-lowering can produce symptomatic hypoglycemia. The risk is higher in older adults, after missed meals, or in patients with reduced kidney function.
Recommendation: Do not start fenugreek on glipizide without telling your prescriber. Check fingerstick glucose more often (before meals and at bedtime) for the first 2-4 weeks and ask whether the glipizide dose should be reduced.
Myo-inositol and D-chiro-inositol improve insulin sensitivity and lower fasting glucose. Glipizide forces pancreatic insulin secretion. Combined, the additive glucose-lowering can produce hypoglycemia, particularly in older adults or after missed meals.
Recommendation: Tell your prescriber before starting inositol on glipizide. Monitor fingerstick glucose more often during the first 2-4 weeks and ask whether the glipizide dose should be reduced.
Glipizide is metabolized primarily by CYP2C9. Silymarin (milk thistle) inhibits CYP2C9 in vitro and has independent hypoglycemic activity demonstrated in type 2 diabetes meta-analyses. The combination can raise glipizide exposure and amplify its glucose-lowering, producing hypoglycemia especially in older adults or after missed meals.
Recommendation: Tell your prescriber before adding milk thistle on glipizide. Monitor fingerstick glucose more often during the first 4 weeks and ask whether the glipizide dose should be reduced.
Quercetin is a flavonoid that inhibits CYP2C9 in human studies (it reduced diclofenac CYP2C9-mediated metabolism at 500 mg twice daily). Glipizide is metabolized primarily by CYP2C9. The combination can raise glipizide exposure and amplify its glucose-lowering, particularly at concentrated supplemental doses (versus dietary quercetin from fruits and vegetables).
Recommendation: Avoid concentrated quercetin supplements (>500 mg/day) on glipizide unless your prescriber agrees. If you take both, monitor fingerstick glucose more often during the first 2-4 weeks and ask whether the glipizide dose should be reduced. Dietary quercetin from foods is unlikely to matter clinically.
Numbered references. Citations throughout the page link here.
Khan H, Zamir A, Imran I et al.. Clinical pharmacokinetics of glipizide: a systematic review. Expert opinion on drug metabolism & toxicology. 2025
Kradjan WA, Witt DM, Opheim KE et al.. Lack of interaction between glipizide and co-trimoxazole. Journal of clinical pharmacology. 1994
Qi H, Wang W, Zhang X et al.. Pharmacokinetics Study of Herb-Drug Interaction of Berberine and Glipizide in Beagle Dogs Using UPLC-MS/MS. International journal of analytical chemistry. 2025
Sukkarieh HH, Husein TH, Bustami RT et al.. Role of age and sex in the incidence of adverse effects among diabetic patients treated with glipizide. Experimental and therapeutic medicine. 2024
Mohammed S, Mahmood T, Shamim A et al.. Correction: Encyclopaedic Review of Glipizide Pre-clinical and Clinical Status. Drug research. 2024
Shaikh S, Vaidya V, Gupta A et al.. A Review on Affordable Combinations in Type 2 Diabetes Care: Exploring the Cost-Effective Potential of Glipizide + Metformin and Glimepiride + Metformin + Pioglitazone. Cureus. 2024
Tandon S, Sarkar S. Glipizide ameliorates human poly(Q) mediated neurotoxicity by upregulating insulin signalling in Drosophila disease models. Biochemical and biophysical research communications. 2023
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack